Pozelimab + Cemdisiran
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Paroxysmal Nocturnal Hemoglobinuria
Conditions
Paroxysmal Nocturnal Hemoglobinuria
Trial Timeline
Jul 29, 2021 → Oct 18, 2023
NCT ID
NCT04811716About Pozelimab + Cemdisiran
Pozelimab + Cemdisiran is a phase 2 stage product being developed by Regeneron Pharmaceuticals for Paroxysmal Nocturnal Hemoglobinuria. The current trial status is completed. This product is registered under clinical trial identifier NCT04811716. Target conditions include Paroxysmal Nocturnal Hemoglobinuria.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06028594 | Pre-clinical | Completed |
| NCT07154745 | Phase 3 | Recruiting |
| NCT05744921 | Phase 3 | Recruiting |
| NCT04940364 | Phase 1 | Completed |
| NCT04811716 | Phase 2 | Completed |
| NCT04888507 | Phase 2 | Completed |
| NCT04601844 | Phase 1 | Completed |
Competing Products
20 competing products in Paroxysmal Nocturnal Hemoglobinuria
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Crovalimab + Eculizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| Crovalimab + Placebo | Chugai Pharmaceutical | Phase 1/2 | 41 |
| Crovalimab + Eculizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| Ravulizumab | AstraZeneca | Pre-clinical | 23 |
| Eculizumab | AstraZeneca | Phase 3 | 77 |
| Danicopan | AstraZeneca | Phase 3 | 77 |
| LNP023 | Novartis | Pre-clinical | 23 |
| Iptacopan (LNP023) | Novartis | Phase 3 | 77 |
| iptacopan | Novartis | Phase 2 | 52 |
| LNP023 | Novartis | Phase 2 | 52 |
| Iptacopan | Novartis | Pre-clinical | 23 |
| Iptacopan | Novartis | Phase 3 | 77 |
| LNP023 + Eculizumab + Ravulizumab | Novartis | Phase 3 | 77 |
| LNP023 | Novartis | Phase 3 | 77 |
| LFG316 + LNP023 | Novartis | Phase 2 | 52 |
| Iptacopan | Novartis | Phase 3 | 77 |
| Crovalimab | Roche | Phase 3 | 77 |
| ABP 959 + Eculizumab | Amgen | Phase 3 | 76 |
| Pegcetacoplan | Swedish Orphan Biovitrum | Pre-clinical | 22 |
| BMS-919373 + Placebo (Matching with BMS-919373) | Bristol Myers Squibb | Phase 2 | 51 |